This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Augustine, C. K. Articles by Tyler, D. S. Search for Related Content PubMed PubMed Citation Articles by Augustine, C. K. Articles by Tyler, D. S.

Targeting N-Cadherin Enhances Antitumor Activity of Cytotoxic Therapies in Melanoma Treatment

Departments of ¹ Surgery, ² Pathology, ³ Pharmacology and Cancer Biology, and ⁴ Medicine, and ⁵ Institute for Genome Sciences and Policy, Duke University; ⁶ Durham VA Medical Center; and ⁷ Adherex Technologies, Inc., Durham, North Carolina

Requests for reprints: Christina K. Augustine, Box 3118 Medical Center, Duke University Medical Center, Durham, NC 27710. Phone: 919-286-0411; Fax: 919-684-6044; E-mail: Christi.augustine{at}duke.edu.

Key Words: N-cadherin • melanoma • melphalan • temozolomide • gene expression

Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin, which is associated with increased motility and invasiveness of the tumor and altered signaling, leading to decreased apoptosis. We hypothesized that the novel pentapeptide (ADH-1), which disrupts N-cadherin adhesion, could sensitize melanoma tumors to the cytotoxic effects of chemotherapy. N-cadherin–expressing human melanoma-derived cell lines were used to generate xenografts in animal models to study isolated limb infusion with melphalan and systemic chemotherapy with temozolomide. We report here that melphalan in combination with ADH-1 significantly reduced tumor growth up to 30-fold over melphalan alone. ADH-1 enhancement of response to melphalan was associated with increased formation of DNA adducts, increased apoptosis, and intracellular signaling changes associated with focal adhesions and fibroblast growth factor receptors. Targeted therapy using an N-cadherin antagonist can dramatically augment the antitumor effects of chemotherapy and is a novel approach to optimizing treatment for melanoma. [Cancer Res 2008;68(10):3777–84]

This article has been cited by other articles:

				B. Zhao, A. Song, R. Haque, F. Lei, L. Weiler, X. Xiong, Y. Wu, M. Croft, and J. Song Cooperation between Molecular Targets of Costimulation in Promoting T Cell Persistence and Tumor Regression J. Immunol., June 1, 2009; 182(11): 6744 - 6752. [Abstract] [Full Text] [PDF]

				Z. A. Kohutek, C. G. diPierro, G. T. Redpath, and I. M. Hussaini ADAM-10-Mediated N-Cadherin Cleavage Is Protein Kinase C-{alpha} Dependent and Promotes Glioblastoma Cell Migration J. Neurosci., April 8, 2009; 29(14): 4605 - 4615. [Abstract] [Full Text] [PDF]

				C. K. Augustine, J. S. Yoo, A. Potti, Y. Yoshimoto, P. A. Zipfel, H. S. Friedman, J. R. Nevins, F. Ali-Osman, and D. S. Tyler Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma Clin. Cancer Res., January 15, 2009; 15(2): 502 - 510. [Abstract] [Full Text] [PDF]